Compass Therapeutics (CMPX) Net Equity Issued and Repurchased (2020 - 2025)

Compass Therapeutics has reported Net Equity Issued and Repurchased for 6 years, with the latest figure at $138.0 million in Q3 2025.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $138.0 million in Q3 2025, while the trailing twelve-month figure through Dec 2025 was $138.0 million (up 661.88% YoY) and the FY2025 annual result came in at $138.0 million, up 661.88% from the prior year.
• Net Equity Issued and Repurchased improved to $138.0 million in Q3 2025 per CMPX's latest filing, from $13000.0 in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $138.0 million in Q3 2025 and troughed at $13000.0 in Q2 2024.
• A 5-year average of $51.9 million and a median of $18.1 million in 2024 frame the typical range for Net Equity Issued and Repurchased.
• The sharpest annual moves came in 2022 and 2024: Net Equity Issued and Repurchased plunged 40.44% in 2022, then sank 99.58% in 2024.
• Over 5 years, Net Equity Issued and Repurchased stood at $128.0 million in 2021, then slumped by 40.44% to $76.2 million in 2022, then plunged by 99.97% to $26000.0 in 2023, then slumped by 50.0% to $13000.0 in 2024, then surged by 1061430.77% to $138.0 million in 2025.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $138.0 million, $13000.0, and $18.1 million for Q3 2025, Q2 2024, and Q1 2024 respectively.